biostudies-literatureUnknown7(15)Vasseur LWhether the LSC17 gene expression can improve risk stratification in the context of next generation sequencing-based risk stratification and measurable residual disease (MRD) in patients with intensively treated AML has not been explored. We analyzed LSC17 in 504 adult patients prospectively treated in the ALFA-0702 trial. RUNX1 or TP53 mutations were associated with higher LSC1 scores while CEBPA and NPM1 mutations were associated with lower scores. Patients with high LSC17 scores had a lower rate of complete response (CR) in a multivariable analysis (odds ratio, 0.41; P = .0007), accounting for European LeukemiaNet 2022 (ELN22), age, and white blood cell count (WBC). LSC17-high status was associated with shorter overall survival (OS) (3-year OS: 70.0% vs 52.7% in patients with LSC17-low Blood advances4024-4034https://www.ebi.ac.uk/biostudies/studies/S-EPMC10410128biostudies-literatureLSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study.PMC10410128Lebon DDombret HHeiblig MCelli-Lebras KBerthon CRecher CFenwarth LDuployez NLambert JDumas PYFigeac MCheok MTerre CItzykson RLemasle Ede Botton SPreudhomme CVillenet CVasseur LfalseLSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study.Whether the LSC17 gene expression can improve risk stratification in the context of next generation sequencing-based risk stratification and measurable residual disease (MRD) in patients with intensively treated AML has not been explored. We analyzed LSC17 in 504 adult patients prospectively treated in the ALFA-0702 trial. RUNX1 or TP53 mutations were associated with higher LSC1 scores while CEBPA and NPM1 mutations were associated with lower scores. Patients with high LSC17 scores had a lower rate of complete response (CR) in a multivariable analysis (odds ratio, 0.41; P = .0007), accounting for European LeukemiaNet 2022 (ELN22), age, and white blood cell count (WBC). LSC17-high status was associated with shorter overall survival (OS) (3-year OS: 70.0% vs 52.7% in patients with LSC17-low 2023-01-01T00:00:00Z2023 Aug2026-05-28T13:05:23.157Z2024-12-04T05:25:29.335ZS-EPMC104101283720585310.1182/bloodadvances.2023010155